Empagliflozin + metformin

Trade Name:

Synjardy

Manufacturer/Distributor:

Boehringer Ingelheim Canada

Classification:

Oral blood glucose lowering agents

ATC Class:

A10BD20 - metformin and empagliflozin

Status:

active

Notice of Compliance (yyyy/mm/dd):

2016/08/03

Date Marketed in Canada (yyyy/mm/dd):

2017/09/18

Presentation:

Tablet: 5 mg empagliflozin + 500 mg metformin. DIN: 02456575

Tablet: 5 mg empagliflozin + 850 mg metformin. DIN: 02456583

Tablet: 5 mg empagliflozin + 1000 mg metformin. DIN: 02456591

Tablet: 12.5 mg empagliflozin + 500 mg metformin. DIN: 02456605

Tablet: 12.5 mg empagliflozin + 850 mg metformin. DIN: 02456613

Tablet: 12.5 mg empagliflozin + 1000 mg metformin. DIN: 02456621

Comments:

For use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes inadequately controlled with metformin OR a sulfonylurea in combination with metformin OR pioglitazone in combination with metformin OR insulin in combination with metformin. It cal also be used in patients already being treated and achieving glycemic control with metformin and empagliflozin as separate tablets OR a sulfonylurea in combination with metformin and empagliflozin as separate tablets OR pioglitazone in combination with metformin and empagliflozin as separate tablets OR insulin in combination with metformin and empagliflozin as separate tablets.

Keywords:

empagliflozin

Keywords:

metformin

Keywords:

diabetes mellitus: type 2

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Escitalopram	Cipralex MELTZ	Selective serotonin reuptake inhibitor	2013/01/15
Esketamine	Spravato	Antidepressant	2020/05/20
Esomeprazole + Naproxen	Vimovo	NSAID + PPI	2011/01/14
Estradiol	Vagifem	Hormone replacement therapy	2011/12/31
Estradiol gel	Divigel	Topical estrogen	2012/10
Estropipate	Ogen
Eszopiclone	Lunesta	Hypnotic	2020/10/20
Ethinyl estradiol + levonorgestrel	Seasonique	Oral contraceptive	2011/04/15
Ethinyl estradiol + norethindrone	Lolo	Oral contraceptive	2014/07/03
Ethinyl estradiol + norgestrel	Ovral	Oral contraceptive
Etonogestrel	Nexplanon	Hormonal contraceptive	2020/08/17
Everolimus	Afinitor	Antineoplastic agent	2010/02/12
Exenatide	Byetta	Incretin mimetic	2011/04/20
Exenatide	Bydureon	Incretin mimetic	2016/02/16
Fampridine	Fampyra	Multiple sclerosis agent	2012/04/17
Febuxostat	Uloric	Xanthine oxidase inhibitor	2010/09/30
Fentanyl	Duragesic	Opioid anaglesic	2009/05/21
Fentanyl	Onsolis	Opioid analgesic	2011/08
Fentanyl	Abstral	Opioid analgesic	2011/06/13
Fesoterodine	Toviaz	Urinary antispasmodic	2012/05/31
Fidaxomicin	Dificid	Antibacterial agent	2012/06
Fingolimod	Gilenya	Sphingosine 1-phosphate receptor modulator	2011/04/04
Flibanserin	ADDYI	CNS agent	2018/02/27
Flumazenil	Anexate	Benzodiazepine antagonist	2012/02/28
Fosfomycin	Monurol	Urinary anti-infective	2012/09/25
Fremanezumab	Ajovy	Anti-calcitonin gene-related peptide	2020/08/04
Galcanezumab	Emgality	CGRP binding antibody	2019/10/02
Gentamicin	Garamycin eye drops; Garamycin ear drops; Garasone eye/ear drops	Antibiotic	2012/04/01
Gilteritinib	Xospata	Antineoplastic agent	2020/02/03
Glasdegib	Daurismo	Antineoplastic agent	2020/08/10
Glecaprevir + pibrentasvir	Maviret	Antiviral agent for treatment of chronic hepatitis C infection	2017/09/13
Gliclazide	Diamicron MR	Sulfonylurea hypoglycemic agent	2010/12/13
Glucagon	Baqsimi	Hyperglycemic agent	2019/11/20
Glycopyrrolate	Cuvposa	Antimuscarinic antispasmodic agent	2018/04/03
Glycopyrronium bromide	Seebri Breezhaler	Anticholinergic agent	2013/01/29
Golimumab	Simponi	Tumor necrosis factor alpha inhibitor (DMARD)	2009/07